Table I. Clinical characteristics of SSc patients
FeatureMicroarray (n = 9)FACS (n = 41)p Values
Age, mean ± SD (y)53.6 ± 12.357.9 ± 11.40.32
Female, n (%)9 (100)37 (90)1
Disease duration, mean ± SD (y)3.6 ± 3.37.0 ± 4.90.06
Diffuse cutaneous SSc, n (%)6 (67)27 (66)1
MRSS, mean ± SD16.4 ± 11.110.0 ± 6.70.19
ILD, n (%)7 (78)23 (56)0.28
FVC, % predicted, mean ± SD88.5 ± 10.385.9 ± 17.10.58
DLCO, % predicted, mean ± SD50.0 ± 12.666.4 ± 21.00.10
Antinuclear Ab, n (%)8 (89)37 (90)1
Anti-topoisomerase I Ab, n (%)5 (56)15 (37)0.45
Anticentromere Ab, n (%)1 (11)8 (20)0.66
Low-dose corticosteroids, n (%)6 (67)20 (49)0.47
Immunosuppressive drug use, n (%)2 (22)9 (22)1
  • DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity.